Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

h therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5 percent of its net sales.
For more information please visit www.us.boehringer-ingelheim.com

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA568014PR

This press release cont
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... The quantum dot market report analyzes the ecosystem of the ... product includes medical devices, display, and others. The others segment ... storage, QD laser, and transistor. The application segment covers the ... The report also provides the geographic view for major regions ... Europe , Asia-Pacific (APAC), and ...
(Date:9/2/2015)... , Sept. 2, 2015 About Duchenne ... X-linked disease, which generally affects the male population. ... weakness. The disease is caused due to mutations ... lack of production of dystrophin (a protein essential ... lack of dystrophin weakens muscle function, causes loss ...
(Date:9/2/2015)... Sept. 2, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... Boston.  The public is welcome to participate in ... BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: Ron ... 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
... May 25, 2011 Each month, millions of women suffer ... of the all-new AZO PMS™ -- the only ... women can now get relief from PMS with a fast ... PMS refers to a wide range of physical ...
... May 25, 2011 Graymark Healthcare, Inc. (NASDAQ: ... services and an innovator in comprehensive care for obstructive sleep ... 1-for-4 reverse stock split, which will be effective after the ... The 1-for-4 reverse stock split will automatically convert all shares ...
Cached Medicine Technology:New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3Graymark Announces 1-for-4 Reverse Stock Split 2
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located ... geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , ... a whole mind-body approach to fitness - we are much more than a gym. ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... gift from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham ... the gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... enables pharmaceutical researchers to participate in interactive programs in which ERT scientists ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... News) -- New research finds that adults who suffered from ... fever -- are nine times more likely to have allergic ... are based on about 1,400 adults who have been followed ... Study. The study participants were assessed in 1968, when they ...
... TUESDAY, April 19 (HealthDay News) -- About 1 in ... -- meaning the virus becomes resistant to multiple drugs ... European study shows. That drug failure rate is ... maintaining viral load suppression in young patients who begin ...
... Amanda Gardner HealthDay Reporter , TUESDAY, April 19 ... for the diagnosis of Alzheimer,s disease could double the number ... guidelines, issued Tuesday by the Alzheimer,s Association and the U.S. ... the last recommendations, which have been in use since 1984. ...
... TUESDAY, April 19 (HealthDay News) -- People who have ... hospital than they did almost two decades ago, but discharges ... a result, Iowa researchers report. Using Medicare data on ... 2008, the researchers found that hospital stays are now averaging ...
... available in French . , Montreal April ... age, yet the reasons for this increasing forgetfulness have not ... older individuals have reduced learning and memory because their minds ... Published in The Quarterly Journal of Experimental Psychology, ...
... Goodwin HealthDay Reporter , TUESDAY, April 19 (HealthDay ... either had or were going to get all of the ... doctor,s advice on immunizations, two new surveys find. Pediatricians ... years of hype about a supposed autism/MMR (measles, mumps, rubella) ...
Cached Medicine News:Health News:Kids' Eczema, Hay Fever Linked to Allergic Asthma Later 2Health News:Children With HIV at Higher Risk of Drug Resistance 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 2Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 3Health News:Spring-cleaning the mind? 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3
Inquire...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
Medicine Products: